Repare Therapeutics to Participate in Two Upcoming Investor Conferences


CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows.

TD Cowen 44th Annual Healthcare Conference Panel Discussion: Gynecological Cancers Date: Tuesday, March 5, 2024 Time: 10:30 a.m. Eastern Time Location: Boston, MA

Bloom Burton 2024 Healthcare Investor Conference Company Overview Date: Tuesday, April 16, 2024 Time: 3:30 p.m. Eastern Time Location: Toronto, ON

A live webcast of the TD Cowen corporate panel discussion and Bloom Burton company overview can be accessed in the Investor section of the Company’s website at A replay of the webcast will be archived on the Company’s website for at least 30 days.

About Repare Therapeutics, Inc. Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Repare Contact: Robin Garner Vice President and Head of Investor Relations Repare Therapeutics Inc.

Investors: Matthew DeYoung Argot Partners

Media: David Rosen Argot Partners 212-600-1902

Source: Repare Therapeutics Inc.

In This Story